Drug Use Investigation of Regorafenib/ STIVARGA for Unresectable, Metastatic or Recurrent Colorectal Cancer
Phase of Trial: Phase IV
Latest Information Update: 26 Apr 2018
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Bayer
- 20 Apr 2018 Status changed from active, no longer recruiting to completed.
- 21 Jan 2017 Results (Data cut off August 2015; n=787) of interim analysis assessing safety and efficacy of regorafenib, presented at the 2017 Gastrointestinal Cancers Symposium
- 06 Jan 2017 Status changed from recruiting to active, no longer recruiting.